Connect with us


A Breakthrough in Biotech May Put Investors at an Advantage

Think about what would happen if a company were to find a cure for diabetes? Investors are flocking to start-ups with promising treatments & 1 small company may hold the key.

Joe Samuel



Think about what would happen if a company were to find a cure for diabetes? This growing segment of the biotech sector has investors flocking to start-ups with promising treatments.

BIG NEWS 10.16.2019 Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)’ Breakthrough Medical Device could Disrupt the Entire Biotech Industry

How Can One Small Biotech Stock Shake Up A Multi-Billion Dollar Market?

Nearly 100 years after the discovery of insulin, Sernova (TSX:SVA) (OTC:SEOVF) is advancing the treatment for type 1 diabetes. Its implantable Cell Pouch™ technology received FDA clearance and is currently intrials in the US. Sernova’s Cell Pouch™, combined with its immune protection technology, offers therapeutic cells local protection from immune system attack.

At a very basic level, this creates an effective, safe, long-term and convenient therapeutic option for patients with chronic disease. But this is no basic technology and it could set a stage to change the lives of millions of people dramatically.

Key Targets Could Suggest Major Disruption For Diabetes Treatment

To truly understand the market potential of Sernova (TSX:SVA) (OTC:SEOVF)’s regenerative medical technology here, we first need to understand that this is already a groundbreaking industry as it stands right now. Regenerative medicine is a next-generation branch of medicine, which broadly involves the development of technologies for replacing, engineering or regenerating cells, tissues or organs to bring back normal function of the body. 

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

Imagine, one day, when diabetes patients no longer need to inject insulin or people affected by hemophilia no longer have to use needles to maintain some sort of normalcy in life. This is now reality and could be a critical point in time to be looking at Sernova (TSX:SVA) (OTC:SEOVF)!

The Cell Pouch™ is manufactured from medical-grade materials, previously approved by the FDA for permanent use in the body in other products. After receiving the sought after US FDA IND, the company has been rapidly pursuing human clinical trials with its Cell Pouch™ System in the United States!

Why is the IND so critical for a biotech company? The United States Food and Drug Administration’s Investigational New Drug (IND) program is how a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved. Sernova (TSX:SVA) (OTC:SEOVF) has this!

It doesn’t just stop there either. The company also received University of Chicago Institutional Review Board approval for their FDA-cleared human clinical trial to investigate the Cell Pouch™ for treatment of type-1 diabetes in individuals with hypoglycemia unawareness. In line with this, Sernova (TSX:SVA) (OTC:SEOVF) has begun implanting its Cell Pouch ™ into patients for treatment of Hypoglycemia Unawareness and diabetes.

Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

This was presented just a few months ago and could show exactly why Sernova (TSX:SVA) (OTC:SEOVF) has started generating more interest across the medical community and public market as well. Sernova (TSX:SVA) (OTC:SEOVF)’s Cell Pouch™ transplanted with islet cells showed initial safety, as well as key efficacy measures, including:

  1. Glucose stimulated C-peptide
  2. Insulin production
  3. Clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.

There was specifically an 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period!

“These results are {…} a paradigm shift in the treatment of this debilitating disease. Our team is looking forward to reporting longer-term results in enrolled patients as the trial progresses.”

– Dr. Witkowski, principal study investigator

These data were so strongly delivered that it has firmly warranted advancing its clinical trials to more patients with type-1 diabetes. We aren’t talking about lab testing the technology on mice; we’re well-beyond that phase. Sernova’s Phase I/II clinical trials will be conducted on multiple human volunteers.

“The preliminary clinical data achieved in this patient with our pre-vascularized implanted Cell Pouch represent an early clinical validation for our regenerative medicine technologies as we pursue safe, efficacious, and transformative treatments for patients with hypoglycemia unawareness in type-1 diabetes.”

– Dr. Philip Toleikis, President and CEO of Sernova Corp.

Why Is Timing So Important Right Now?

Let’s get one thing straight, clinical trials take time but the closer it gets to a favorable outcome, the bigger the potential can be for a company. Furthermore, with each milestone can come even more attention to a company.

When it comes to the diabetes trials, Sernova (TSX:SVA) (OTC:SEOVF) has already shown favorable outcomes and now it’s time to scale the trial size to show it can be repeated multiple times with the same positive results.

The global diabetes therapeutics market was valued at $66.993 billion in 2016 and is estimated to reach $186.842 billion by 2023 [1]. This simple fact has created massive buzz across the biotechnology industry and further spurred a big buyout trend specifically for companies looking at diabetes treatments outside of the normal injection of insulin.

This wildfire of Big Pharma buying out clinical-stage companies could put a countdown on companies like Sernova (TSX:SVA) (OTC:SEOVF), and the proof is already showing to be in the billions:

Private Equity Firm Platinum Equity Buys LifeScan For $2.1 billion[2]

PHC Holdings Corporation Acquires Thermo Fisher’s Pathology Business For $1.14 Billion [3]

Novo Nordisk acquired diabetes company Ziylo for $800 million[4]

Vertex to Acquire Semma Therapeutics for $950 Million[5]

And it’s this most recent acquisition of Semma by Vertex that could be the writing on the wall for Sernova (TSX:SVA) (OTC:SEOVF). Semma Therapeutics is a privately held biotechnology company focusing on the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. But the most important part here is that Semma’s results have only been shown from proof-of-concept in animals.

Sernova (TSX:SVA) (OTC:SEOVF) is already in the clinic and on top of that, where Semma was valued at $950 billion in this deal, Sernova currently trades at a value of less than $40 million!

Analysts Are Bullish On Sernova (TSX:SVA) (OTC:SEOVF)

Besides it being ahead of the curve even compared to companies getting bought out for big money, analysts have become increasingly bullish on Sernova (TSX:SVA) (OTC:SEOVF)!

Echelon Wealth Partners analyst Douglas Loe thinks Sernova (TSX:SVA) (OTC:SEOVF) has massive upside [6]. Not only did the analyst give a $1 price target for the stock he also backed up his “Speculative Buy” rating with a clear explanation of the company’s future prospects.

“Cell Pouch met virtually all of the performance specifications that it would need to meet to demonstrate its medical utility as a regenerative medicine-enabling cell reservoir platform.”

On top of this, Loe explains that he sees no reason to assume that the Cell Pouch™ as used by other patients in the trial with similar disease profiles cannot exhibit similarly strong performance.

“We expect new case data from the University of Chicago T1D/Cell Pouch program to generate new case data in coming quarters and for the trial to lead directly into formal pivotal T1D testing once concluded, possibly by end-of-F2020, and we look for tangible updates on both the hemophilia A and hypothyroidism preclinical programs within the next few quarters.”

Looking Beyond Diabetes: Sernova (TSX:SVA) (OTC:SEOVF) Builds Further Onto Its Pipeline

There’s no denying the potential of Sernova (TSX:SVA) (OTC:SEOVF)’s Cell Pouch™ for diabetes but that’s just the tip of the iceberg. In fact, Sernova (TSX:SVA) (OTC:SEOVF) has several key indications for other diseases:

sernova pipeline

Specifically, its Hemophilia A treatment could be next in line. Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. The disease occurs in 1 in 5,000 live male births and is about four times as common as hemophilia B. The number of people with hemophilia in world is not well known, but estimated at more than 400,000 people [7].

Medications to treat hemophilia cost an average of more than $270,000 annually per patient [8]. Furthermore, Grand View Research estimates the global hemophilia market to be valued at US$11.1 billion in 2018.


Key therapies analyzed in the hemophilia market include replacement therapy, Immune Tolerance Induction therapy, and gene therapy. Gene therapy is an evolving field focused on identifying defective DNA bases and reinstating functional ones. Hence, this segment is expected to present industry players with the most lucrative opportunities over the forecast period.

First In The World

Development of a product capable of producing an effective level of Factor VIII within the Cell Pouch™ environment has the potential to provide hemophilia A patients with better protection against dangerous episodes of excessive bleeding and greatly reduce annual therapy costs. Significant progress has already been achieved in the development of what is being called a ‘first in world’ personalized regenerative medicine therapy for the treatment of Hemophilia A patients by the HemAcure Consortium.

Ground-Breaking Developments Achieved by the Consortium:  

  • A reliable procedure has been implemented to isolate and maintain required endothelial cells from a sample of the patient’s blood.
  • Using a novel gene correction process, the cells have been corrected and tuned to reliably produce the required Factor VIII to treat Hemophilia A.
  • The cells have been successfully scaled up to achieve the required therapeutic number, and cryopreserved for shipping and future transplant into the implanted Cell Pouch.

“Sernova’s Cell Pouch platform technologies are achieving important world-first milestones in both diabetes and now hemophilia, two significant clinical indications which are being disrupted by its regenerative medicine approach aimed at significantly improving patient quality of life.” – Dr. Philip Toleikis, Sernova President and CEO.

Elite Team Of Management

Key management has built a business around industry-disrupting technology and the years of experience show why:

Dr. Philip M. Toleikis – President & CEO

Dr. Toleikis is currently President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations.

While at Sernova, Dr. Toleikis has secured over $20 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies.

Dr. Toleikis is the author of multiple issued patents, over 110 patent applications, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.

Frank Holler – Director and Chairman – Board of Directors

Mr. Holler is currently President &CEO of Ponderosa Capital Inc and has a long history of serving at top roles. Mr. Holler previously served as Chairman &CEO of BC Advantage Funds Ltd., a venture capital firm investing in emerging technology companies in British Columbia. He was also President and CEO of Xenon Pharmaceuticals Inc., a NASDAQ listed, genomics-based drug development company. This is in addition to his experience serving as President and CEO of ID Biomedical Corporation, a TSX/Nasdaq vaccine development company and being a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed biotechnology company.

Jeffrey Bacha – Director

Mr. Bacha has consulted with and lead a number of life sciences companies. He co-founded DelMar Pharmaceuticals in 2010 and led the company’s growth through its listing on NASDAQ in 2016 and currently serves as a member of the company’s board of directors. Previously he served as the Chief Executive Officer and Chairman of the Company prior to recruiting both a seasoned independent Chair and interim Chief Executive to join the DelMar Pharmaceuticals leadership team.

He is a seasoned executive leader with 20 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States, and Europe. His experiences include successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets.

Deborah Brown – Director

Deborah M. Brown is currently Managing Partner at Accelera Canada Ltd. Ms. Brown has served as President of EMD Serono, a division of Merck KGaA, Executive Vice President at Serono US, General Manager, Director of Marketing, and Business Unit Director at Serono Canada and Manager, International Regulatory at Pasteur Merieux Connaught. Ms. Brown is a former Board Chair of Rx&D and former board member of BIOTECanada. She sits on the board of several corporate and not-for-profit organizations, including Life Sciences Ontario and the Hamilton/Burlington SPCA.

James Parsons –Director

Mr. Parsons is currently Chief Financial Officer of Trillium Therapeutics Inc. He was also Vice President Finance and Corporate Secretary at DiaMedica Therapeutics Inc.

Mr. Parsons has a broad background in the life sciences industry across therapeutics, diagnostics and device companies and over 25 years of financial management experience. Mr. Parsons has secured over $300 million of various forms of financing during his career and has advised and assisted on over $200 million of product licensing deals.

Clinical Stage Biotech Stocks Could Present First-In-Line Opportunity

This isn’t just a story about breakthrough diabetes or hemophilia treatment technologies. We’re also talking about a bigger picture with clinical-stage biotechnology companies. Case in point, anyone can call a blue-chip biotech stock a success. But were they there when that company was in its early clinical or event preclinical stages? If that question were asked to most about Pfizer or Bayer today, the answer would likely be “no.”

But there are countless examples of clinical-stage companies hitting it big after reporting meaningful trial results. And it’s usually the early onlookers who may have the upper hand at capitalizing:

Deciphera Pharmaceuticals, Inc. more than doubled after reporting positive top line results from a phase 3 clinical study from $19.95 to as high as $42.99… 115%

CorMedix, Inc. Exploded From $6.30 to $13.60 Following Positive Interim Study Results … 116%

CEL-SCI Corporation Jumps From $3.00 March 2019 To Nearly $9 Following Series Of Phase Trial Updates… 199%

Corindus Vascular Robotics, Inc. Rallies from $0.99 At the Start of 2019 to highs of $4.27 Following Agreement to Be Acquired By Siemens Healthineers Just 8 Months Later…  331%

Zynex Rallies From Just $2.60 in January to highs of $11.75… 351%

And these are just a few examples of biotech stock catalysts that sent these companies soaring in 2019! While many of the drugs in development are two-to-five years from reaching the market – if they get that far – betting on the feverish deal activity could give investors a chance to profit near term.

It doesn’t take a rocket scientist to see that biotech catalyst can trigger massive runs, especially in smaller companies.  So with major progress being observed on a number of pipeline therapies, Sernova (TSX:SVA) (OTC:SEOVF) may be approaching critical mass, as it were. The market for its drugs has become ripe with opportunities and the latest trend in the biotech sector could lead the way for a new groundswell to begin before the end of the year.

With the recent progress that the company has seen from its early trials, the fervent demand for new therapies, and the stampede of investments flooding into the market from major biotech leaders, it may be time to start looking at small-cap biotech stocks before the Main Street rush opens the floodgates.

Top 5 Reasons To Have Sernova (TSX:SVA) (OTC:SEOVF) On Your Stock List

1. Major acquisition trends from large-cap biotechs could open near term opportunity for promising drug therapies from smaller cap companies

2. Favorable trial results demonstrate considerable potential from Sernova (TSX:SVA) (OTC:SEOVF) treatment pipeline. More near term potential could present itself leading up to new Cell Pouch ™ trials & put it head-to-head with leading companies.

3. Additional benefits of Sernova (TSX:SVA) (OTC:SEOVF)‘s therapies extend to other hotbed markets like Hemophilia A, human growth hormone deficiency, parathyroid hormone deficiency and Parkinson’s disease. This has also earned it enough attention to warrant a $1 price target and “Speculative Buy” Rating by analysts.

4. The market opportunity for Diabetes therapy alone concerns a $186 billion market.

5. Early-stage catalyst for clinical biotech stocks have presented first-mover advantages & Sernova (TSX:SVA) (OTC:SEOVF) has several major milestones that could point toward further clinical developments to come.

biotech stocks to buy or sell

End Notes:
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading
Click to comment


3 Penny Stocks Looking To Change The Biotech Industry

Jon Phillip



biotechnology stocks

The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.

Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.


GT Biopharma Inc. (GTBP)

One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.

biotechnology stocks to buy now

So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.

TriKE Therapy

One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.

“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.

Conatus Pharmaceuticals Inc. (CNAT)

This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.

biotechnology stocks to watch

In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.

Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.

Nuvectra Corporation (NVTR)

To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.

breakthrough biotech stocks to watch

Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.

Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.


biotechnology stocks

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here

Continue Reading


Are These Biotech Names On Your October Watch List?

Joe Samuel



biotech stock price

Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.

Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

best biotechnology stocks to buy now

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.

Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)                                           

The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.

The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.

Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.

Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)

The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.

The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.

list of healthcare stocks to watch

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.

Continue Reading


Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch

Joe Samuel



biotech penny stocks to buy

Biotech & Healthcare ETF’s Made New October Highs; Watching Sector Stocks?

There are certain sectors in the stock market that regularly excite investors. Much of that has to do with the core strength of the sector in question. While tech has been such a sector for more than three decades now, the biotech sector has also been a sector that has helped investors make excellent returns for many years now.

Over the last few trading sessions, both the IBB and XLV ETF’s have taken off to make new October highs. So why wouldn’t healthcare and biotechnology catch someone’s eye?

The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.

GT Biopharma (GTBP) Pops After HIV Data Presentation

GT Biopharma, Inc. (GTBP) is an immuno-oncology company focused on innovative treatments based on the Company’s patent-pending TriKE™ technology. It’s also a biotech stock that has been on the move this month. Earlier in October the company announced key presentation data on its HIV TriKE™ platform.

GT Biopharma (GTBP) Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

Tim Schacker , M.D., Jeffrey S. Miller , M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg.

biotechnology stocks to watch

Research findings from Dr. Schacker’s and Dr. Miller’s laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE™. This could be a big step for the company and one that has caught some attention this month.

In comparison, the use of anti-retroviral drugs have substantially improved the health and increased the longevity of individuals infected with the human immunodeficiency virus (HIV). But these drugs are designed to suppress virus replication to help modulate progression to AIDS and to limit further transmission of the virus. In this case, GTBP’s HIV-TriKE™ was actually able to kill HIV in the reservoir.

Achillion Pharmaceuticals (ACHN) Jumps On Buyout

One of the biotech stocks that made a remarkable move this week was Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) after it was announced that the company was going to be acquired by Alexion Pharmaceuticals. According to the announcement, Achillion is going to be acquired in a deal worth $930 million.

 It is a deal that is going to be completed entirely in cash. Alexion is paying a premium of 73% above the closing price of the Achillion stock on Tuesday. That works out to a price of $6.30 a share and on Tuesday, the stock had closed at $3.65 a share.

The announcement lit a fire on the Achillion stock and it zoomed by as much as 75% on Wednesday. Considering the sort of premium that is being paid, it is not really a surprise for most market watchers to take notice.

Atossa Genetics (ATOS) Gains On Phase 2 clinical study

The other biotech stock that is in the news today is that of Atossa Genetics Inc (NASDAQ:ATOS). The clinical-stage biopharmaceutical company that is engaged in developing treatments for breast cancer, made a major announcement.


It has been announced that its microcatheter technology has been approved for a Phase 2 clinical study by the Institutional Review Board (IRB).

The technology helps in administering fulvestrant in breast cancer patients and could have major implications for the company’s long term growth. The market believed so as well and the Atossa stock climbed as much as 4.50% after the news broke on Wednesday.

biotechnology stocks to buy now

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!

Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (


Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact